Conduct Hit-to-Lead Progression Studies on Interventional Agents: Identification of Anti-HIV Lead Compounds

NIH RePORTER · NIH · N01 · $403,478 · view on reporter.nih.gov ↗

Abstract

Preclinical Services for HIV Therapeutics: The purpose of these Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. The scope of work encompasses activities that range from basic research and initial product discovery to activities required for clinical trials and/or product licensure. These services may also be used to support product discovery and development leading to Investigational New Drug Application (IND), Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID Division of AIDS will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The purpose of this task order is to develop potential compounds with activity to block HIV infection, inhibit HIV gene expression and replication, or cure infected cells of HIV infection.

Key facts

NIH application ID
10927005
Project number
75N93021D00010-0-759302300001-1
Recipient
SOUTHERN RESEARCH INSTITUTE
Principal Investigator
CORINNE AUGELLI-SZAFRAN
Activity code
N01
Funding institute
NIH
Fiscal year
2023
Award amount
$403,478
Award type
Project period
2023-09-01 → 2024-08-31